Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin and Omega 3 Combination Therapy in T2DM with Dyslipidemia
NCT05365438Phase 4Recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of omega-3-acid triglycerides in type 2 diabetes mellitus (T2DM), dyslipidemia and atherosclerosis (3 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Carotid intima media thickness at 24 weeks. Started Oct 2022; status: recruiting.
02
Drugs
omega-3-acid triglycerides
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemiaatherosclerosis
Beyond the preview
Go deeper on NCT05365438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365438.